S
SinoMab BioScience Ltd
HKEX:3681
SinoMab BioScience Ltd
HKEX:3681
Price:
1.51
HKD
-4.43%
Market Closed
Market Cap:
HK$2.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
SinoMab BioScience Ltd
HKEX:3681
|
HK |
Income Statement
Earnings Waterfall
SinoMab BioScience Ltd
SinoMab BioScience Ltd
Income Statement
SinoMab BioScience Ltd
SinoMab BioScience Ltd
Currency: CNY
| Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Interest Expense |
2
|
0
|
6
|
0
|
5
|
0
|
7
|
0
|
9
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
26
N/A
|
26
N/A
|
0
N/A
|
1
N/A
|
1
N/A
|
2
+48%
|
2
N/A
|
0
N/A
|
0
N/A
|
|
| Gross Profit | ||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
+29%
|
1
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||
| Operating Expenses |
(163)
|
(150)
|
(332)
|
(303)
|
(259)
|
(214)
|
(229)
|
(198)
|
(161)
|
(136)
|
(108)
|
|
| Selling, General & Administrative |
(72)
|
(55)
|
(133)
|
(134)
|
(83)
|
(99)
|
(98)
|
(82)
|
(68)
|
(57)
|
(46)
|
|
| Research & Development |
(103)
|
(146)
|
(199)
|
(191)
|
(180)
|
(165)
|
(135)
|
(124)
|
(95)
|
(72)
|
(82)
|
|
| Other Operating Expenses |
13
|
50
|
1
|
23
|
4
|
50
|
4
|
9
|
1
|
(6)
|
21
|
|
| Operating Income |
(163)
N/A
|
(150)
+8%
|
(306)
-104%
|
(277)
+10%
|
(259)
+6%
|
(214)
+17%
|
(229)
-7%
|
(197)
+14%
|
(161)
+18%
|
(136)
+15%
|
(108)
+21%
|
|
| Pre-Tax Income | ||||||||||||
| Interest Income Expense |
40
|
(6)
|
18
|
(41)
|
(42)
|
(61)
|
(13)
|
(2)
|
(12)
|
(8)
|
(5)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
17
|
0
|
(1)
|
0
|
(12)
|
0
|
7
|
|
| Pre-Tax Income |
(123)
N/A
|
(156)
-27%
|
(288)
-85%
|
(318)
-10%
|
(284)
+11%
|
(274)
+3%
|
(243)
+11%
|
(200)
+18%
|
(185)
+7%
|
(144)
+22%
|
(105)
+27%
|
|
| Net Income | ||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(123)
|
(156)
|
(288)
|
(318)
|
(284)
|
(274)
|
(243)
|
(200)
|
(185)
|
(144)
|
(105)
|
|
| Net Income (Common) |
(123)
N/A
|
(156)
-27%
|
(288)
-85%
|
(318)
-10%
|
(284)
+11%
|
(274)
+3%
|
(243)
+11%
|
(200)
+18%
|
(185)
+7%
|
(144)
+22%
|
(105)
+27%
|
|
| EPS (Diluted) |
-0.12
N/A
|
-0.16
-33%
|
-0.29
-81%
|
-0.32
-10%
|
-0.29
+9%
|
-0.27
+7%
|
-0.24
+11%
|
-0.19
+21%
|
-0.17
+11%
|
-0.13
+24%
|
-0.09
+31%
|
|
Switch to:
Switch to:
See Also
Discover More
